In the second ESC 2021 episode of Parallax, Dr Ankur Kalra’s guest is Dr. Mirvat Alasnag, interventional Cardiologist and Director of Catheterization Laboratory at the King Fahad Armed Forces Hospital (KFAFH) in Saudi Arabia. Dr Alasnag was a programme committee member at this year’s ESC and regional PI of one of the late-breaking trials presented.

Ankur invites Mirvat to review the interventional cardiology highlights of the congress. Mirvat summarises the background and latest evidence from the trials and their importance. Ankur and Mirvat discuss the strategies they apply currently and how they think the novel data will guide their decision-making.

Trials covered in detail include:

STOPDAPT-2 ACS: one-month dual antiplatelet therapy followed by clopidogrel monotherapy in acute coronary syndrome
TOMAHAWK: immediate angiography after out-of-hospital cardiac arrest
ENVISAGE-TAVI AF: edoxaban vs. vitamin K antagonists after TAVI in patients with atrial fibrillation
RIPCORD 2: does routine pressure wire assessment influence management strategy of coronary angiography for diagnosis of chest pain?
MASTER DAPT: dual antiplatelet therapy after coronary stenting in high bleeding risk patients

Questions and comments can be sent to “podcast@radcliffe-group.com” and may be answered by Ankur in the next episode. Guest @mirvatalasnag hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.